Cytogenetic abnormalities commonly associated with acute lymphoblastic leukemia (ALL) are detected by fluorescence in situ hybridization (FISH). Probes for TCF3/PBX1 t(1;19), BCR/ABL1-ASS1 t(9;22), CDKN2A (9p21.3), KMT2A (MLL)(11q23.3), ETV6/RUNX1 t(12;21)/(iAMP21), IGH (14q32.3), TP53 (17p13.1) are included in the ALL FISH Profile.
disease state indication(s)
Acute lymphoblastic leukemia (ALL), B lymphoblastic leukemia/lymphoma
The ALL FISH Profile detects cytogenetic abnormalities commonly associated with acute lymphoblastic leukemia (ALL). Identification of specific abnormalities define various subtypes of ALL that have different prognosis and responsiveness to specific therapies.
Fluorescence in situ hybridization (FISH)
specimen type and requirements
Peripheral blood: 5-6 mL in sodium heparin (green-top) tube.
Bone marrow: 2-3 mL in sodium heparin (green-top) tube.
Bodily fluids: Bodily fluids for diagnostic testing of hematological cancers (subject to specimen viability): Preferred transport in equal parts RPMI.
Lymphoid tissue: Transport in RPMI.
FFPE tissue: no decalcification.
Note: Use refrigerated cold pack for transport. Make sure cold pack is not in direct contact with specimen.
DO NOT FREEZE.
Probe Prioritization: If samples are insufficient to complete the whole FISH panel, Genoptix will prioritize testing in the following order: BCR/ABL1-ASS1, KMT2A, CDKN2A, TCF3/PBX1, ETV6/RUNX1/(iAMP21), TP53, and IGH, unless directed otherwise by the client.
Tech-only (TC): 3 days
Global: 5 days
medicare moldx cpt code
Laboratory developed test (LDT)
Global or Tech-only (TC)